Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review.

Front Immunol · 2023 · PMC10104167 · PMID 37063914

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

a decreasing trendp=0.09so close (0.05 < p ≤ 0.1)

Although the naked virus did not show a significant difference compared to the control group (p=0.3791), the VSV-IFNβ-infected mBOECs group showed a decreasing trend of lung tumor burden compared to the control (p=0.09).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.